ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

SIMPLE SUMMARY: Peptide-based cancer vaccines require adjuvants to increase their immunogenicity to mount an antigen-specific reliable immune response. We have previously shown that immunization with self-adjuvanting peptide-based vaccines issued from our KISIMA vaccine platform, and targeting tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascolutti, Roberta, Yeturu, Lakshmi, Philippin, Géraldine, Costa Borges, Stéphane, Dejob, Magali, Santiago-Raber, Marie-Laure, Derouazi, Madiha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600632/
https://www.ncbi.nlm.nih.gov/pubmed/36291919
http://dx.doi.org/10.3390/cancers14205134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600632/
https://www.ncbi.nlm.nih.gov/pubmed/36291919
http://dx.doi.org/10.3390/cancers14205134

Ejemplares similares